Arteris: vp and general counsel Paul L Alpern sold 10,148 shares

What happened

• Paul L Alpern, vice president and general counsel, exercised options for 6,500 shares (4,000 at $0.56 and 2,500 at $9.28) on Oct 1, 2026, and acquired those shares for a total of $25,440. The filing also shows derivative disposals for 4,000 and 2,500 shares at $0.00 on Oct 1, 2026.
• The filing reports open-market sales totaling 10,148 shares: 6,500 shares sold on Oct 1, 2026 at a weighted average $23.84 for $154,933, and 3,648 shares sold on Oct 2, 2026 in four trades at $24.64 each for a total of $89,899. Total proceeds reported from sales equal $244,832.

Key details

• Transaction dates and prices:
  • Oct 1, 2026: exercised 4,000 shares at $0.56 and 2,500 shares at $9.28 (acquired); sold 6,500 shares at a weighted average $23.84 (range $23.41 to $24.15 per footnote).
  • Oct 1, 2026: derivative disposals of 4,000 and 2,500 shares at $0.00 (reported as derivative transactions).
  • Oct 2, 2026: sold 692, 765, 1,181, and 1,010 shares at $24.64 each (total 3,648 shares).
• Shares owned after the transaction: not reported in this filing.
• Relevant footnotes:
  • F1: the Oct 1-2 sales were made pursuant to a 10b5-1 trading plan adopted Feb 23, 2026.
  • F2: the Oct 1 sale price is a weighted average; individual prices ranged from $23.41 to $24.15.
  • F3: some shares were sold to satisfy tax withholding obligations arising from restricted stock unit releases ("sell to cover").
  • F4/F5: vesting schedules for the incentive and non-qualified options are noted in the filing.
• Filing date and timeliness: Form filed Oct 5, 2026; transactions reported for Oct 1 and Oct 2, 2026. No late filing is indicated in the information provided.

Why it may matter

• Options exercise: the filing shows exercised options for 6,500 shares and matching derivative disposals at $0.00 for the same amounts, plus open-market sales, which indicates the exercised shares were not fully retained (i.e., shares were sold as part of the exercise or to cover obligations).
• 10b5-1 and sell-to-cover: the filing states sales were under a 10b5-1 plan and that some sales were to satisfy tax withholding from RSU releases.
• A filing does not show why the insider traded or why the company acted.